Search

everythinglearnresearchcommunity

for

Search:↓

Triptolide effectively and safely reduces actinic keratosis lesions in mice.

Lack of KSR1 stops certain skin tumors in mice.

Raltegravir may cause hair loss in some patients.

Rat skin takes up and processes testosterone differently than other organs, with testosterone being more important for the skin than its metabolite 5α-DHT.

A new method allows for controlled, long-lasting delivery of retinoic acid through the skin with less inflammation.

Deleting the Trf1 protein in mice is safe and may help prevent cancer without major side effects.

Targeted radionuclide therapy shows promise for improving head and neck cancer treatment but needs more research.

Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.

Ion-paired risedronate significantly increases skin penetration without irritation compared to risedronate alone.

Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.

Two non-steroidal antiandrogens, RU 58841 and RU 56187, form a common metabolite at different rates, which may influence their effects; RU 56187 could be used for prostate cancer treatment and RU 58841 for acne treatment.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.

Blocking TRPV3 may help treat itch in dry skin conditions.

Targeting the TRPV4 channel may help treat intestinal diseases.

Rac1 is crucial for normal hair structure and pigmentation.

Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.

A new method can quickly and accurately detect drugs in hair.

Certain changes to the B-ring of androgen receptor ligands can increase their effectiveness for potential treatments of muscle and bone conditions.

Trastuzumab deruxtecan is effective for advanced breast cancer but has side effects like nausea and fatigue.

Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.

New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.

TRPA1 is crucial for mechanical sensitivity in skin sensory neurons.

A mutation in the VDR gene affects hair cycling without needing ligand binding.

RXRα is crucial for proper immune response and links diet to immune function.

Ayurvedic treatment successfully regrew hair in a 19-year-old with alopecia areata in 2 months.

Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.

RANK is a key target in breast cancer treatment due to its role in tumor growth and bone metastasis.

TRPV channels are important in osteoarthritis and could be key to new treatments.